Seeking Alpha

Spencer Osborne

 
View as an RSS Feed
View Spencer Osborne's Comments BY TICKER:
Latest  |  Highest rated
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    Robert....

    I assure you. I am not missing the point. I am very well aware of it.

    Your second paragraph is a good example of the professionalism points made earlier:

    "You are quoting something you picked up from another article most probably and that original information was just dead wrong and totally misleading."

    I am not quoting anything from another article. Your assumption is off base.

    Your next point:

    "I just went back and read the label and nowhere does it state that Afrezza is not intended to replace long acting insulin. Of course it would never say that because Afrezza has nothing to do with long acting insulin."

    I think you may have meant one thing and types another. Breaking down your statement, you essentially say that the label doe not say, " Afrezza is not intended to replace long acting insulin"

    Please refer to the label again under the LIMITATIONS FOR USE section.

    Limitations of Use:
    • AFREZZA is not a substitute for long-acting insulin. AFREZZA must be used in combination with long-acting insulin in patients with type 1 diabetes mellitus.
    • AFREZZA is not recommended for the treatment of diabetic ketoacidosis [see Warning and Precautions (5.6)].
    • The safety and efficacy of AFREZZA in patients who smoke has not been established.
    The use of AFREZZA is not recommended in patients who smoke or who have recently stopped smoking.

    If you look at the first bullet point in the limitattions section it clearly states, " AFREZZA is not a substitute for long-acting insulin."

    I do not know how much more simple I could be other than to go through my paragraph point by point:

    1. "MannKind had a long and arduous road to approval in the United States."

    Do you agree or disagree?

    2. "The company's inhaled insulin is a novel approach to maintaining control of insulin levels."

    Do you agree or disagree?

    3. "However, the drug's labeling....makes it clear that it is not a replacement for long-acting insulin.

    Do you agree or disagree?

    4. "Some analysts feel the label is restrictive"

    Do you agree or disagree?

    5. "It is thought that it will be well-accepted by consumers because it is not delivered by injection."

    Do you agree or disagree?

    Nowhere, nowhere, nowhere was it insinuated that Afrezza may not be a standalone product. Antone thinking that was insinuated is simply the victim of their own imagination or is inserting their own preconceived notions into the equation.
    Aug 12 10:53 PM | Likes Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    Robert.....

    As a person that has the contributor badge, you have a certain level of "responsibility" above that of an average reader. There have been many times that I have disagreed with a contributor on Seeking Alpha. The way I handle that is to send that person a private message expressing my thoughts. This is how long standing contributors handle such situations.

    In this response you just made you pulled my thought process out of context. The entire thought process was:

    "MannKind had a long and arduous road to approval in the United States. The company's inhaled insulin is a novel approach to maintaining control of insulin levels. However, the drug's labeling, which some analysts feel is restrictive, makes it clear that it is not a replacement for long-acting insulin. It is thought that it will be well-accepted by consumers because it is not delivered by injection."

    That thought process was included in the article to simply give the average reader a small insight into what the company is and what the drug is. It was not intended to be a scientific diatribe of the merits and pitfalls of Afrezza or Mannkind.

    The label states:

    "Afrezza is not a substitute for long-acting insulin. Afrezza must be used in combination with long-acting insulin in patients with type 1 diabetes, and it is not recommended for the treatment of diabetic ketoacidosis, or in patients who smoke"

    The point was simply to give an average reader a small amount of flavor. Perhaps some investors are just too jaded after being invested in this equity for so long and pinning high hopes on making enough money on this stock to buy a new house. The type of attitude I saw in response to this article is something I have come across many times with stocks that are driven by retail investors. heck, to this day SiriusXM has shareholders waiting for $20 per share a decade later.

    Ironically, the focal point of too many became something that had very little to do with the basis of the article. The voices of a few get published here. The voices of much more expressed a thank-you to me in private.

    From an investment standpoint, the best product in the world may not represent a good investment. I separate my feelings for a product from the equity and how it will perform. I have made money on stocks with sub-par products because the valuation was there to allow money to be made. I have had money sit idle or even lost money on companies with great products because there was simply no room for value appreciation.

    There are serious people crunching serious numbers now that this deal has been announced. This story is now shifting from pure speculation to one that needs to consider fundamentals. Growing from pure speculation has growing pains in most cases. This is why my opinion is that managing expectations is critical....even if it may cause near term pain.

    I closing, I rarely make comment on the articles of other writers, and if I do I am very measured in what I say and how I say it. It is a professional courtesy that used to be well understood, but in recent years has started to fall by the wayside. While I do not write for a living, nor was I trained in Journalism in my education, I have been writing for over a decade now and learned some lessons along the way about how to conduct myself with others that write. I am not perfect, but I try to always be careful when addressing another contributor.

    Aug 12 10:38 PM | Likes Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    Jam....

    How long do you think it will take to get to $1 billion in net sales? Let's see how well you manage your own expectations
    Aug 12 03:58 PM | Likes Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    Jamo....

    We are talking about mannkind as an investment....not sanfoi.

    How much revenue needs to filter to mannkind to maintain its $3 billion market cap? How much is needed to see growth? These are the types of things that will be thought about and analyzed going forward.

    Again, this deal will be assessed for a while before the street decides where the valuation should be.

    Think about it. It takes $1 billion in net sales to bring $350 million to mannkind.

    You act as if I am anti mannkind. I am not. I simply assess what I think the equity will do. At the moment, a critical point us managing expectations.
    Aug 12 01:09 PM | Likes Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    Jam....

    The article was written early in the morning with the news. Articles are not published right away.

    Heavy lifting is with sanfoi, but mannkind relies on the success or failure of its partner. Maintaining a market cap of $3 billion will have its challenges.

    Mannkind needs a successful launch. Expectations need to be properly managed
    Aug 12 09:41 AM | Likes Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    Just....


    1. I stated the stance of some analysts

    2. Read the lable
    Aug 12 07:31 AM | Likes Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    Jam....

    You could ask a question in a civil manner, or you could jump to erroneous conclusions, make uninformed statements, and turn this into a circus. People of intellect learn to ask questions first.

    Mannkind will boil down to sakes and the revenues it can generate. There are still many unknowns about this launch. Final price point, rebates, marketing, sales reps, etc. these are the times when the speculation needs to prove itself out.

    Mannkind needs to be crystal clear with the street in manning expectations. The biggest mistake would be to allow expeditions to inflate to a point that is not attainable. It was a mistake Arena made and the equity suffered. The longer these questions are out there, the more turbulence this equity will see.

    We need to learn the terms (or at least as much as we can) of the deal. What is the cost of the $175 million that was fronted (if any). How will the company account for the $150 million and over what time period? What type of expenses are expected prior to the drug becoming profitable? Will the $175 million be enough to cover that?

    There has been good news, but there are now more serious questions that mannkind needs to manage.

    Despite your total lack of respect in your post, I have outlined several reasons why it is not all smooth sailing ahead. I am not beating bearish. I am simply being realistic.

    You are welcome to add your thoughts, but I would suggest you bring more to the table than name calling.
    Aug 11 10:42 PM | Likes Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    Jam....

    Nowhere in my article did I say that the drug could not be a standalone therapy. I pointed out some sentiments that analysts have expressed. Again, I pointed out bull side, bear side, and bull side. If anything I spoke more to the bullish side of this drug.
    Aug 11 10:32 PM | Likes Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    Robert....

    With all due respect, for you to stand here and attempt to lecture me on this forum is downright unprofessional at best.

    The original statement I made was perfectly fine in the context in which it was delivered. Some wanted a point of clarity (being rude and sophomoric in the process) and I made that clarity.

    You saying that I am not aware or did not research is so far off of the mark that I am almost speechless!

    1. I did not write in any shape or form that this drug could not be a stand alone therapy.

    2. I was not in any way advancing any position. I sandwiched what some analysts are saying on the bearish side between two of the bullish stances.

    I would highly suggest, as a contributor here, that you find a more professional manner in which to offer up your critique.

    Have a nice evening.

    Aug 11 08:09 PM | 1 Like Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    B&B.....

    My point was a discussion about the near term action on this equity. This was not an article about the science of mannkind, how doctors treat diabetes, the competitive landscape, or anything else in that vein.

    What we had here was a severe over-reaction by an investor that is likely over-passionate about his investment. He came out swinging with no real reason to do so. His foolishness was pointed out, and he went about his way.
    Aug 11 05:56 PM | 1 Like Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    MR....

    You calling me names is not really very meaningful in the end. It does not really reflect on me, but instead on you.

    I try to take the higher road, but also get attacked for not being a pom-pom waver.

    Me being defensive is simply that. I do not really have to sit back and allow someone to throw baseless things at me. I simply identified them as baseless and identified why they are baseless. A person of strong character would step up and admit the mistake and move on. I thought that vperhaps you had that in you. I was wrong I guess.

    At least you are now moving on.


    Best of luck
    Aug 11 03:45 PM | 1 Like Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    Mr.....

    Thank you for the well wishes. That is the most civil thing you have said to me. It is unfortunate. I am sorry that I called you out in a manner that might be embarrassing to you, but you were way off base.

    Be Well
    Aug 11 03:13 PM | Likes Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    Robert....

    Thank you for the comment.

    I suspect that the person jumped to a conclusion because he was sensative to the subject. The paragraph in question was:

    "The company's inhaled insulin is a novel approach to maintaining control of insulin levels. However, the drug's labeling, which some analysts feel is restrictive, makes it clear that it is not a replacement for long-acting insulin. It is thought that it will be well-accepted by consumers because it is not delivered by injection."

    The intent of the paragraph was to give a little flavor on the drug within the piece, not to give a thesis about the science. Simply stated, the reader jumped to some very wrong conclusions. Why they did that I am not sure. I did add the term "long-acting" in front of insulin to make the point clear (even though it was not a major part of the article - a point that would be pretty clear to anyone).

    The first part of the paragraph spoke to Afrezza being a novel approach to maintaining insulin levels.

    I was guilty of not being clear enough in an anecdotal part of the article. I corrected that. Other are guilty of simply being jerks. I can not do anything about that other than call them out for bad behavior.
    Aug 11 03:09 PM | Likes Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    Mr...

    Forgive me for pointing this out, but it needs to be said

    Let's review:

    "You clearly don't understand the difference between prandial and basil insulin"

    This statement you made was poorly researched and not accurate

    "It's pathetic you bottom feeders write about hot topics to get clicks without half a clue what you're writing about."

    You throw a label of bottom feeder to me with no knowledge of who I am, what I do, or why I do it. You assigned this label to me within minutes of this article being published. Is such behavior something that you would teach your children? Do you want them to cast judgement in the manner in which you have? You attacked me, unproked. Do you feel good about yourself?

    "I would love a lengthy discussion with you on diabetes as it is clear you do not fully understand what you're writing about by reading a label."

    I would rather not converse with someone that is so quick to judge without having all of the information. That being said, you are free to offer up your "education" to all readers. Some may learn a few things and gain value from it. However, I would not recommend that you assume that people do not know something. Remember, the focus of this article was nowhere near a scientific discussion.

    What you could have Done:

    You could have made an intelligent comment and made a statement such as, "Spencer, Could you look into how you worded the third paragraph where you state that it is not a replacement for insulin. I would think that if you put the words "long-acting" in front of insulin it would be more accurate"

    You did not choose the high road. You chose the road of casting insults and making assumptions that are baseless. Think about that.

    For the record, I did add the word "long-acting" in front of insulin.

    I would like to thank you for giving me a shining example of how not to act that I can show my children. I would never want them to grow up to be as aggressive, judgmental, and assuming as you demonstrate. Hopefully this was just a small rush to judgement on your part and you will be man enough to see the error and recant your hurtful and ignorant words.

    Good Day.
    Aug 11 02:54 PM | 1 Like Like |Link to Comment
  • MannKind Inks Deal For Afrezza - Can Still See Stormy Days Ahead [View article]
    Mr....

    You are saying that I do not understand, but that is where you err. I do understand. Try to consider that:

    1. This article was not about insulin...it was about a new deal.

    2. This article was not designed to be an intensive scientific discussion.

    3. You are making various assumptions about me without basis.

    I have not written about Mannkind before. However, I have been following it for a few years now and watching it not as an investment, but from a personal standpoint as I have family with diabetes.

    You seem to have let your passion dictate your thoughts. That is fine. It happens.

    Clicks do not motivate me, so again, you are throwing out an assumption that is baseless, unfounded, and clearly not well researched.

    HMMMMMM

    seems that you are doing EXACTLY what you are accusing me of.

    Take a deep breath. Please
    Aug 11 02:33 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
6,862 Comments
5,293 Likes